Advertisement

Document › Details
Merck KGaA. (6/18/19). "Press Release: Merck Places Hybrid Bond Amounting to € 1.5 Billion. Placement Is an Important Part of the Financing of the Planned Acquisition of Versum Materials, Inc.". Darmstadt.
> Tranches of € 1 billion and € 500 million placed
> Transaction significantly oversubscribed
Merck, a leading science and technology company, today successfully placed a hybrid bond amounting to € 1.5 billion. The placement is part of the financing of the planned acquisition of U.S.-based company Versum Materials, Inc. (NYSE: VSM), which was announced in April 2019.
The placement comprises two tranches, both of which have a maturity of 60 years. The first tranche amounting to € 500 million pays a coupon of 1.625% and includes an early redemption option for Merck after 5.5 years. The second tranche of € 1 billion pays a coupon of 2.875 %, including an early redemption option after 10 years. Having received equity credit treatment from all three rating agencies Standard & Poor’s, Moody’s and Scope, the placement thus supports Merck’s credit rating. The bond is equal in rank to the existing hybrid bonds and subordinated to all of Merck’s other existing financial liabilities.
“We had secured a solid financing structure for the proposed acquisition of Versum right from the start. Today’s placement of hybrid capital shows that we remain committed to supporting our credit rating and a conservative financial policy,” said Marcus Kuhnert, Member of the Executive Board and Chief Financial Officer of Merck.
The acquisition of Versum is expected to strengthen the Performance Materials business sector. Versum is a leading supplier of innovation-driven, high-purity process chemicals, gases and equipment for semiconductor manufacturing. The transaction is expected to close in the second half of 2019, subject to regulatory clearances and the satisfaction of other customary closing conditions. Versum stockholders already gave their approval at a special meeting on June 17, 2019.
The placement was significantly oversubscribed and generated strong international demand, with the majority being placed in France, the United Kingdom and Germany. The bond achieved a well-diversified distribution among a wide range of institutional investors such as fund managers, insurance companies and banks. The bookrunners of the transaction were Merck’s relationship banks.
Merck is rated “A” (stable outlook) by Standard & Poor’s, “A–“ (stable outlook) by Scope and “Baa1” (stable outlook) by Moody’s.
For more information, please contact Gangolf Schrimpf
+49 6151 72-9591
All Merck Press Releases are distributed by e-mail at the same time they become available on the Merck Website. Please go to www.merckgroup.com/subscribe to register online, change your selection or discontinue this service.
About Merck
Merck, a leading science and technology company, operates across healthcare, life science and performance materials. Around 52,000 employees work to make a positive difference to millions of people’s lives every day by creating more joyful and sustainable ways to live. From advancing gene editing technologies and discovering unique ways to treat the most challenging diseases to enabling the intelligence of devices – the company is everywhere. In 2018, Merck generated sales of € 14.8 billion in 66 countries.
Scientific exploration and responsible entrepreneurship have been key to Merck’s technological and scientific advances. This is how Merck has thrived since its founding in 1668. The founding family remains the majority owner of the publicly listed company. Merck holds the global rights to the Merck name and brand. The only exceptions are the United States and Canada, where the business sectors of Merck operate as EMD Serono in healthcare, MilliporeSigma in life science, and EMD Performance Materials.
Record changed: 2019-07-22 |
Advertisement

More documents for Merck (DE) (Group)
- [1] Merck KGaA. (1/8/21). "Press Release: Merck Announces Formation of Merck Digital Ethics Advisory Panel". Darmstadt....
- [2] Merck KGaA. (1/7/21). "Press Release: Merck Acquires AmpTec to Expand mRNA Capabilities for Vaccines, Treatments and Diagnostics". Darmstadt....
- [3] Merck KGaA. (12/7/20). "Press Release: Merck Expands Life Science Production Capacities in the United States". Darmstadt....
- [4] Merck KGaA. (12/3/20). "Press Release: Merck and Artios Pharma Announce a Global Strategic Collaboration on Novel DNA Damage Response Targets in Oncology". Darmstadt....
- [5] Merck KGaA. (11/9/20). "Press Release: Merck Announces Out-licensing Agreement for Investigational Atacicept with Vera Therapeutics [Not intended for UK and US based media]". Darmstadt....
- [6] Merck KGaA. (10/12/20). "Press Release: Merck Licenses CRISPR Genome-Editing Technology to PanCELLa and Takara Bio USA". Darmstadt....
- [7] Precigen, Inc.. (10/9/20). "Press Release: Precigen Announces Merck KGaA, Darmstadt, Germany Increases Ownership Position Through Exercise of Convertible Note". Germantown, MD....
- [8] Merck KGaA. (10/8/20). "Press Release: Merck Celebrates Topping-Out Ceremony for New Membrane Production Plant". Darmstadt....
- [9] Merck KGaA. (10/6/20). "Press Release: Merck Announces Out-Licensing Agreement for Phase II-ready Anti-ADAMTS5 Nanobody for Osteoarthritis [Not intended for UK and US based media]". Darmstadt....
- [10] NanoSyrinx Ltd.. (9/30/20). "Press Release: Synthetic Biology Start Up NanoSyrinx Secures Capital to Develop Its Fully Customisable Platform for Intra-cellular Engineering". Coventry....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]
Advertisement

» top